Levosimendan. A promising future drug for refractory cardiac failure in children?

Supriya Kushwah1, Ashutosh Kumar2, K S Sahana3

  • 1Assistant Professor, Department of Pediatrics, Yenepoya Medical College, Deralakatte, Mangalore, Karnataka, India.

Indian Heart Journal
|April 9, 2016
PubMed

Insights

Levosimendan effectively treated a young girl with severe heart failure from viral myocarditis. This inotropic agent improved cardiac function without increasing oxygen demand, offering a new treatment option.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Intravenous positive inotropic agents are crucial for acute decompensated heart failure (ADHF) with left ventricular systolic dysfunction.
  • Levosimendan is a novel inotropic agent with unique mechanisms: ATP-dependent potassium channel opening and calcium sensitization.

Observation:

  • A 12-year-old girl presented with viral myocarditis and dilated cardiomyopathy, experiencing biventricular failure and severe left ventricular dysfunction.
  • Her condition was refractory to standard heart failure management protocols.

Findings:

  • Treatment with levosimendan resulted in significant clinical improvement.
  • Levosimendan enhanced cardiac contractility and performance while providing vasodilation, notably without increasing myocardial oxygen demand.

Implications:

  • This case highlights levosimendan's potential efficacy in pediatric patients with severe heart failure unresponsive to conventional therapies.
  • Levosimendan represents a promising therapeutic option for complex pediatric cardiomyopathies and myocarditis.
  • Further research into levosimendan's role in pediatric cardiovascular critical care is warranted.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
508
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
738
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
533
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605